Genomic correlates of variability in immune response to an oral cholera vaccine

European Journal of Human Genetics

Volumn 21, Issue 9, 2013, Pages 1000-1006

  Majumder, Partha P ^a,b   Sarkar Roy, Neeta ^a,b   Staats, Herman ^c   Ramamurthy, T ^d   Maiti, Sujit ^b,e   Chowdhury, Goutam ^d   Whisnant, Carol C ^f   Narayanasamy, K ^g,h   Wagener, Diane K ^f  

^a NATIONAL INSTITUTE OF BIOMEDICAL GENOMICS   (India)

^b INDIAN STATISTICAL INSTITUTE   (India)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d NATIONAL INSTITUTE OF CHOLERA AND ENTERIC DISEASES   (India)

^e UNIVERSITY OF WESTERN ONTARIO   (Canada)

^f RTI INTERNATIONAL   (United States)

^g The Centre for Genomic Application TCGA   (India)

^h SphaeraPharma ^*  (India)

Author keywords

anti LPS antibody assay; association; haplotype; SNP; vibriocidal assay

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CHEMOKINE RECEPTOR CXCR4; CHOLERA VACCINE; INTERLEUKIN 16; MARCO PROTEIN; TIGHT JUNCTION PROTEIN; TNFAIP3 PROTEIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; BACTERIAL IMMUNITY; BLOOD SAMPLING; CHOLERA; CONTROLLED STUDY; DEMOGRAPHY; DIARRHEA; FEMALE; GENE EXPRESSION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC DIFFERENCE; GENOTYPE; HAPLOTYPE; HUMAN; IMMUNE RESPONSE; IMMUNOGENETICS; INDEPENDENT VARIABLE; INDIA; INNATE IMMUNITY; INTESTINE EPITHELIUM CELL; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; PRIORITY JOURNAL; PUBLIC HEALTH; SEROCONVERSION; SINGLE NUCLEOTIDE POLYMORPHISM; TIGHT JUNCTION; UPREGULATION; VALIDATION PROCESS; VIBRIO CHOLERAE; WORLD HEALTH ORGANIZATION;

BACTERIA (MICROORGANISMS); VIBRIO CHOLERAE;

ADMINISTRATION, ORAL; ADULT; ANTIBODIES, BACTERIAL; ANTIBODY FORMATION; CHEMOKINE CXCL12; CHOLERA; CHOLERA VACCINES; DNA-BINDING PROTEINS; FEMALE; GENE FREQUENCY; GENOME, HUMAN; HAPLOTYPES; HUMANS; IMMUNITY, ACTIVE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, IMMUNOLOGIC; VACCINATION;

EID: 84882454665     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2012.278     Document Type: Article

References (65)

1. World Health Organization. Cholera: global surveillance summary, 2008. Weekly Epid Rec 2009; 84: 309-324.
2. World Health Organization. Meeting of the Strategic Advisory Group of Experts on immunization October 2009-conclusions and recommendations. Weekly Epid Rec 2009; 50: 526-528.
3. Date KA, Vicari A, Hyde TB et al: Considerations for oral cholera vaccine use during outbreak after earthquake in Haiti 2010-2011. Emerg Infect Dis 2011; 17: 2105-2112.
4. Tappero JW, Tauxe-Emer RV: Lessons learned during public health response to cholera epidemic in haiti and the dominican republic. Emerg Infect Dis 2011; 17: 2087-2093.
5. Institute of Medicine: New Vaccine Development Establishing Priorities Volume II Diseases of Importance in Developing Countries. Washington DC: National Academy Press, 1986.
6. World Health Organization: Cholera, 2010. Weekly Epid Rec 2011; 86: 325-340.
7. Ryan ET: The cholera pandemic still with us after half a century Time to rethink. PLoS Negl Trop Dis 2011; 5: e1003.
8. Nandy RK, Sengupta TK, Mukhopadhyay S, Ghosh AC: A comparative study of the properties of Vibrio cholera 0139 01 and other non-01 strains. J Med Microbiol 1995; 42: 251-257.
9. Levine MM, Black RE, Clements ML, Cisneros L, Nalin DR, Young CR: Duration of infection-derived immunity to cholera. J Infect Dis 1981; 143: 818-820.
10. World Health Organization. Global Task Force on Cholera Control. Cholera Vaccines A new public health tool? Report of a WHO meeting 10-11 December 2002 Geneva Switzerland World Health Organization 2002, pp 14.
11. Sinclair D, Abba K, Zaman K, Qadri F, Graves PM: Oral vaccines for preventing cholera. Cochrane Database Syst Rev 2011; Issue 3 Art No CD008603.
12. Provenzano D, Kovác P, Wade WF: The ABCs (Antibody B cells and Carbohydrate epitopes) of cholera immunity considerations for an improved vaccine. Microbiol Immunol 2006; 50: 899-927.
13. Clemens JD, Sack DA, Harris JR et al: ABO blood groups and cholera new observations on specificity of risk and modification of vaccine efficacy. J Infect Dis 1989; 159: 770-773.
14. Glass RI, Holmgren J, Haley CE et al: Predisposition for cholera of individuals with O blood groupPossible evolutionary significance. Am J Epidemiol 1985; 121: 791-796.
15. Harris JB, Khan AI, LaRocque RC et al: Blood group immunity and risk of infection with Vibrio cholerae in an area of endemicity. Infect Immun 2005; 73: 7422-7427.
16. Lagos R, Avendano A, Prado V et al: Attenuated live cholera vaccine strain CVD 103- HgR elicits significantly higher serum vibriocidal antibody titres in persons of blood group O. Infect Immun 1995; 63: 707-709.
17. Ramamurthy T, Wagener D, Chowdhury G, Majumder PP: A large study on immunological response to a whole-cell killed oral cholera vaccine reveals that there are significant geographical differences in response and that O blood group individuals do not elicit a higher response. Clin Vaccine Immunol 2010; 17: 1232-1237.
18. Poland GA: Variability in immune response to pathogens using measles vaccine to probe immunogenetic determinants of response. Am J Hum Genet 1998; 62: 215-220.
19. Poland GA, Jacobson RM, Colbourne SA et al: Measles antibody seroprevalence rates among immunized Inuit Innu and Caucasian subjects. Vaccine 1999; 17: 1525-1531.
20. Milich DR, Leroux-Roels GG: Immunogenetics of the response to HBsAg vaccination. Autoimmun Rev 2003; 2: 248-257.
21. Zuckerman JN: Nonresponse to hepatitis B vaccines and the kinetics of anti-HBs production. J Med Virol 1996; 50: 283-288.
22. Gupta D, Faridi MM, Aggarwal A, Kaur I: Seroprevalence of anti-Vi antibodies and immunogenicity of Typhim Vi vaccine in children. Hum Vaccine 2008; 4: 305-308.
23. Sur D, Ochiai RL, Bhattacharya SK et al: A cluster-randomized effectiveness trial of Vi typhoid vaccine in India. N Engl J Med 2009; 361: 403-405.
24. Kimman TG, Vandebriel RJ, Hoebee B: Genetic variation in the response to vaccination. Community Genet 2007; 10: 201-217.
25. Kruskall MS, Alper CA, Awdeh Z, Yunis EJ, Marcus-Bagley D: The immune response to hepatitis B vaccine in humans inheritance patterns in families. J ExpMed 1992; 175: 495-502.
26. Gelder CM, Lambkin R, Hart KW et al: Associations between human leukocyte antigens and nonresponsiveness to influenza vaccine. J Infect Dis 2002; 185: 114-117.
27. Poland GA, Ovsyannikova IG, Jacobson RM: Immunogenetics of seasonal influenza vaccine response. Vaccine 2008; 26: D35-D40.
28. Poland GA, Ovsyannikova IG, Jacobson RM: Vaccine immunogenetics bedside to bench to population. Vaccine 2008; 26: 6183-6188.
29. van Eden W, de Bries RRP, Stanford JL, Rook GAW: HLADR3 associated genetic control of response to multiple skin tests with new tuberculins. Clin Exp Immunol 1983; 52: 287-292.
30. Wang C, Tang J, Song W, Lobashevsky E, Wilson CM, Kaslow RA: HLA and cytokine gene polymorphisms are independently associated with responses to hepatitis B vaccination. Hepatology 2004; 39: 978-988.
31. Anh DD, Canh do G, Lopez AL et al: Safety and immunogenicity of a reformulated Vietnamese bivalent killed whole-cell oral cholera vaccine in adults. Vaccine 2007; 25: 1149-1155.
32. Pulendran B, Kumar P, Cutler CW, Mohamadzadeh M, Van Dyke T, Banchereau J: Lipopolysaccharides from distinct pathogens induce different classes of immune responses in vivo. J Immunol 2001; 167: 5067-5076.
33. Jin P, Wang E: Polymorphism in clinical immunology-from HLA typing to immunogenetic profiling. J Transl Med 2003; 1: 8.
34. Majumder PP, Staats HF, Sarkar-Roy N et al: Genetic determinants of immuneresponse to a polysaccharide vaccine for typhoid. HUGO J 2009; 3: 17-30.
35. Ovsyannikova IG, Haralambieva IH, Vierkant RA, Pankratz VS, Jacobson RM, Poland GA: The role of polymorphisms in Toll-like receptors and their associated intracellular signaling genes in measles vaccine immunity. Hum Genet 2011; 130: 547-561.
36. Benenson AS, Saad A, Mosley WH: Serological studies in cholera 2 The vibriocidal antibody response of cholera patients determined by a microtechnique. Bull World Health Organ 1968; 38: 277-285.
37. Sarkar-Roy N, Mondal D, Bhattacharya P, Majumder P: A novel statistical algorithm for enhancing the utility of HapMap data to design genomic association studies in non- HapMap populations. Int J Data Mining Bioinf 2011; 5: 706-716.
38. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D: Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006; 38: 904-909.
39. Benjamini Y, Hochberg Y: Controlling the false discovery rate a practical and powerful approach to multiple testing. J Roy Statist Soc Ser B Methodological 1995; 57: 289-300.
40. Conneely KN, Boehnke M: So many correlated tests so little time! Rapid adjustment of P values for multiple correlated tests. Am J Hum Genet 2007; 81: 1158-1168.
41. Han B, Kang HM, Eskin E: Rapid and accurate multiple testing correction and power estimation for millions of correlated markers. PLoS Genet 2009; 5: e1000456.
42. Stephens M, Smith N, Donnelly P: A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001; 68: 978-989.
43. Eko FO, Schukovskaya T, Lotzmanova EY et al: Evaluation of the protective efficacy of Vibrio cholerae ghost VCG; candidate vaccines in rabbits. Vaccine 2003; 21: 3663-3674.
44. Tarique AA, Kalsy A, Arifuzzaman M et al: Transcutaneous immunization with a Vibrio cholerae O1 Ogawa synthetic hexasaccharide conjugate following oral whole-cell cholera vaccination boosts vibriocidal responses and induces protective immunity in mice. Clin Vaccine Immunol 2012; 19: 594-602.
45. Sack DA, Sack RB, Nair GB, Siddique AK: Cholera. Lancet 2004; 363: 223-233.
46. Kaper JB, Morris JG, Levine MM: Cholera. Clin Microbiol Rev 1995; 8: 48-86.
47. Clemens JD, van Loon F, Sack DA et al: Field trial of oral cholera vaccines in Bangladesh serum vibriocidal and antitoxic antibodies as markers of the risk of cholera. J Infect Dis 1991; 163: 1235-1242.
48. Saha D, LaRocque RC, Khan AI et al: Incomplete correlation of serum vibriocidal antibody titer with protection from Vibrio cholerae infection in urban Bangladesh. J Infect Dis 2004; 189: 2318-2322.
49. Losonsky GA, Yunyongying J, Lim V et al: Factors influencing secondary vibriocidal immune responses Relevance for understanding immunity to cholera. Infect Immun 1996; 64: 10-15.
50. Alam MM, Riyadh MA, Fatema K et al: Antigen-specific memory B-cell responses in Bangladeshi adults after one- or two-dose oral killed cholera vaccination and comparison with responses in patients with naturally. Clin Vaccine Immunol 2011; 18: 844-850.
51. Leung DT, Rahman MA, Mohasin M et al: Memory B Cell and Other Immune Responses in Children Receiving Two Doses of an Oral Killed Cholera Vaccine Compared to Responses following Natural Cholera Infection in Bangladesh. Clin Vaccine Immunol 2012; 19: 690-698.
52. Levine MM: Immunogenicity and efficacy of oral vaccines in developing countries lessons from a live cholera vaccine. BMC Biol 2010; 8: 129.
53. Serazin AC, Shackelton LA, Wilson C, Bhan MK: Improving the performance of enteric vaccines in the developing world. Nat Immunol 2010; 11: 769-773.
54. LaRocque RC, Sabeti P, Duggal P et al: A variant in long palate lung and nasal epithelium clone 1 is associated with cholera in a Bangladeshi population. Genes Immun 2009; 10: 267-272.
55. Shin OS, Uddin T, Citorik R et al: LPLUNC1 modulates innate immune responses to Vibrio cholera. J Infect Dis 2011; 204: 1349-1357.
56. Agle KA, Vongsa RA, Dwinell MB: Chemokine stimulation promotes enterocyte migration through laminin-specific integrins. Am J Physiol Gastrointest Liver Physiol 2011; 301: G968-G980.
57. Ou G, Rompikuntal PK, Bitar A et al: Vibrio cholerae cytolysin causes an inflammatory response in human intestinal epithelial cells that is modulated by the prtv protease. PLoS ONE 2009; 4: e7806.
58. Poggi A, Carosio R, Fenoglio D et al: Migration of Vd1 and Vd2T cells in response to CXCR3 and CXCR4 ligands in healthy donors and HIV-1-infected patients competition by HIV-1 Tat. Blood 2003; 103: 2205-2213.
59. Jennner RG, Young RA: Insights into host responses against pathogens from transcriptional profiling. Nat Rev Microbiol 2005; 3: 281-294.
60. Kolodziej LE, Lodolce JP, Chang JE et al: TNFAIP2 maintains intestinal barrier function and supports epithelial cell tight junctions. PLoS One 2011; 6: e26352.
61. Fung EY, Smyth DJ, Howson JM et al: Analysis of 17 autoimmune disease-associated variants in type 1 diabetes identifies 6q23/TNFAIP3 as a susceptibility locus. Genes Immunity 2009; 10: 188-191.
62. Kraal G, van der Laan LJW, Elomaa O, Tryggvason K: The macrophage receptor MARCO. Microbes Infect 2000; 2: 313-316.
63. Van der Laan LJW, Dopp EA, Haworth R et al: Regulation and functional involvement of macrophage scavenger receptor MARCO in clearance of bacteria in vivo. J Immunol 1999; 162: 939-947.
64. Sankala M, Brännström A, Schulthess T et al: Characterization of Recombinant Soluble Macrophage Scavenger Receptor MARCO. J Biol Chem 2002; 277: 33378-33385.
65. Alam MM, Riyadh MA, Fatema K et al: Antigen-specific memory B-cell responses in bangladeshi adults after one- or two-dose oral killed cholera vaccination and comparison with responses in patients with naturally acquired cholera. Clin Vac Immuol 2011; 18: 844-850.